Skip to main content
Clinical Trials/KCT0007273
KCT0007273
Recruiting
未知

A 8 week, Randomized, Double-Blind, Placebo-Controlled Clinical Trial for the Evaluation of the Efficacy and Safety of CAEC on Immune Function

AEKYUNG Industry0 sites100 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
AEKYUNG Industry
Enrollment
100
Status
Recruiting
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
3 years ago
Study Type
Interventional Study
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\) Male or female subjects aged from 30 to 70 years old.
  • 2\) White blood cell (WBC) ranged from 4000 to 8000 cells/ul at visit 1\.
  • 3\) Perceived stress scale (PSS) above 16 score.
  • 4\) Subjects who agreed to participate in this study and subjects who signed written informed consent voluntarily.

Exclusion Criteria

  • 1\) Subjects who currently taking medications for an underlying disease, etc
  • 2\) Hypertension (systolic blood pressure above 140mmHg or diastolic blood pressure above 90mmHg, after 10 minutes of rest)
  • 3\) Diabetes (FBS(fasting blood sugar) level greater than 126 mg/dl or taking drugs due to diabetes)
  • 4\) TSH below 0\.1µIU/mL or above 10µIU/mL
  • 5\) Vaccinated within 3 months before visit1 (influenza, COVID\-19, herpes zoster, etc.)
  • 6\) Patients with diseases that can affect the immune response, such as adult asthma and rhinitis
  • 7\) Before visit 1, donate whole blood within 2 months or donate component blood within 4 weeks person who performed
  • 8\) AST(aspartate aminotransferase) or ALT(alanine aminotransferase) is more than 3 times the normal upper limit
  • 9\) Creatinine blood level is more than 1\.5 times the normal upper limit
  • 10\) Subjects who have used steroids within 1 month based on visit 1

Outcomes

Primary Outcomes

Not specified

Similar Trials